Abstract
It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.
| Original language | English |
|---|---|
| Pages (from-to) | 527-534 |
| Number of pages | 8 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 11 |
| Issue number | 5 |
| State | Published - May 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Drug Discovery
Cite this
IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. / Mitchell, Jesse; Dimov, Vesselin; Townley, Robert G.
In: Current Opinion in Investigational Drugs, Vol. 11, No. 5, 05.2010, p. 527-534.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease
AU - Mitchell, Jesse
AU - Dimov, Vesselin
AU - Townley, Robert G.
PY - 2010/5
Y1 - 2010/5
N2 - It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.
AB - It is widely accepted that T-helper 2 cell (Th2) cytokines play an important role in the maintenance of asthma and allergy. Emerging evidence has highlighted the role of IL-13 in the pathogenesis of these diseases. In particular, IL-13 is involved in the regulation of IgE synthesis, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration, and has been associated with the regulation of certain chemokine receptors, notably CCR5. Thus, targeting IL-13 and its associated receptors may be a therapeutic approach to the treatment of asthma and/or allergy. Pharmaceutical and biotechnology companies are researching various strategies, based on this approach, aimed at binding IL-13, increasing the level of the IL-13 decoy receptor, IL-13Rα2, or blocking the effect of the chemokine receptor CCR5. This review focuses on the therapeutic potential of anti-IL-13 agents and their role in the treatment of asthma and allergy.
UR - http://www.scopus.com/inward/record.url?scp=77952126162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952126162&partnerID=8YFLogxK
M3 - Review article
VL - 11
SP - 527
EP - 534
JO - Current Opinion in Investigational Drugs
JF - Current Opinion in Investigational Drugs
SN - 1354-3784
IS - 5
ER -